Asafa Powell, Sherone Simpson Sue Supplement Maker

Couch Mode
Via Digicel Sportsmax:

Doyle Management, the company that manages Asafa Powell and Sherone Simpson, is to sue Epiphany D1 on behalf of the athletes for US$8 million following their failed drugs tests.

Both athletes tested positive for oxilofrine at their national championships in June 2013 and were provisionally suspended for 18 months by a Jamaican anti-doping disciplinary panel . That sentence was subsequently reduced to six months after an appeal to the Court of Arbitration for Sport (CAS) in 2014.

 According to Athletics Weekly, during the CAS hearing, it was argued that Epiphany D1 manufacturers had failed to specify in their listed ingredients that oxilofrene was included.

“We found out later that the supplement company actually put something else on the label that they didn’t put in the product,” said Paul Doyle, Powell’s agent and the director of Doyle Management.

“They put on the label Acacia Rigidula, which is a natural plant that grows in Texas and has a sort of stimulant property just as caffeine would have, but they didn’t actually put that in there, they put oxilofrine in instead.”

Having made the discovery, which was confirned by the World Anti-Doping Agency and the USA’s Food and Drug Administration (FDA), Doyle told AW that they had no recourse but to file suit as it is the only way to clear the names of Powell and Simpson.

“The only situation for redemption for Asafa is to sue the supplement company and that’s what we’ve done; we’re suing them on behalf of Asafa and Sherone for over eight million dollars because to be honest the damage is stronger than eight million dollars in the way that he (Powell) has been affected, this will be with him for the rest of his life and that is what kills me inside,” said Doyle.
Facebook Conversations
Back To Top